Matinas BioPharma Holdings, Inc. announced the planned retirement of Raphael J. Mannino, Chief Scientific Officer of the Company, who joined Matinas in 2015 following its acquisition of Aquarius Biotechnologies, Inc. Dr. Mannino has informed the Company that he intends to retire from employment effective December 31, 2022, whereupon he has agreed to transition to a consulting role and will continue to serve as a key strategic advisor to the Company.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1599 USD | -0.06% | +0.63% | -26.04% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-26.04% | 40.11M | |
+18.15% | 124B | |
+18.02% | 112B | |
+5.07% | 22.94B | |
-12.75% | 22.22B | |
-9.86% | 17.02B | |
-14.97% | 16.88B | |
-39.94% | 16.87B | |
+2.80% | 13.63B | |
+27.39% | 11.61B |
- Stock Market
- Equities
- MTNB Stock
- News Matinas BioPharma Holdings, Inc.
- Matinas BioPharma Holdings, Inc. Announces Retirement of Raphael J. Mannino, Chief Scientific Officer, Effective December 31, 2022